Addus HomeCare (ADUS) Stock Price, News & Analysis

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Addus HomeCare in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ADUS shares.
View ADUS analyst ratings or view top-rated stocks.

7 equities research analysts have issued 1 year price targets for Addus HomeCare's stock. Their ADUS share price targets range from $88.00 to $118.00. On average, they expect the company's stock price to reach $103.83 in the next twelve months. This suggests a possible upside of 6.8% from the stock's current price.
View analysts price targets for ADUS or view top-rated stocks among Wall Street analysts.

Addus HomeCare's stock was trading at $92.85 at the beginning of 2024. Since then, ADUS shares have increased by 4.7% and is now trading at $97.19.
View the best growth stocks for 2024 here.

Addus HomeCare saw a decrease in short interest in March. As of March 31st, there was short interest totaling 354,100 shares, a decrease of 9.9% from the March 15th total of 393,100 shares. Based on an average trading volume of 113,700 shares, the days-to-cover ratio is currently 3.1 days. Approximately 2.2% of the company's stock are short sold.
View Addus HomeCare's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our ADUS earnings forecast.

Addus HomeCare Co. (NASDAQ:ADUS) posted its quarterly earnings results on Monday, February, 26th. The company reported $1.21 earnings per share for the quarter, beating the consensus estimate of $1.04 by $0.17. The firm earned $276.35 million during the quarter, compared to analyst estimates of $274.02 million. Addus HomeCare had a trailing twelve-month return on equity of 9.70% and a net margin of 5.91%.

ETFs with the largest weight of Addus HomeCare (NASDAQ:ADUS) stock in their portfolio include SPDR S&P Health Care Services ETF (XHS), Janus Henderson Small Cap Growth Alpha ETF (JSML), Invesco S&P SmallCap Health Care ETF (PSCH), Argent Mid Cap ETF (AMID), BNY Mellon Women's Opportunities ETF (BKWO) and Texas Capital Texas Equity Index ETF (TXS).iShares U.S. Healthcare Providers ETF (IHF).

91 employees have rated Addus HomeCare Chief Executive Officer Dirk Allison on Glassdoor.com. Dirk Allison has an approval rating of 51% among the company's employees. This puts Dirk Allison in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Addus HomeCare investors own include AbbVie (ABBV), Bank of America (BAC), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Verizon Communications (VZ), CVS Health (CVS), Pfizer (PFE), Ulta Beauty (ULTA), Cisco Systems (CSCO) and Walt Disney (DIS).

Addus HomeCare's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wasatch Advisors LP (1.89%), Tributary Capital Management LLC (1.28%), Bridge City Capital LLC (0.19%), Chatham Capital Group Inc. (0.13%), State of Alaska Department of Revenue (0.06%) and Los Angeles Capital Management LLC (0.06%). Insiders that own company stock include Brian Poff, Darby Anderson, David W Tucker, Esteban Lopez, Michael D Wattenbarger, Monica Raines, R Dirk Allison, Roberton James Stevenson, Sean Gaffney and W Bradley Bickham.
View institutional ownership trends.

Shares of ADUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.